Save information for later
Sign Up

Learn About Plasmacytoma

Who are the top Plasmacytoma Local Doctors?
Elite in Plasmacytoma
Hematology Oncology | Oncology
Elite in Plasmacytoma
Hematology Oncology | Oncology

MD Anderson

2130 W Holcombe Blvd, Univ Of Tx M D Ande Life Sciences Pla, 
Houston, TX 
Languages Spoken:
English
Offers Telehealth

Robert Orlowski is a Hematologist Oncology specialist and an Oncologist in Houston, Texas. Dr. Orlowski and is rated as an Elite provider by MediFind in the treatment of Plasmacytoma. His top areas of expertise are Multiple Myeloma, Plasmacytoma, Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Philippe A. Moreau
Elite in Plasmacytoma
Elite in Plasmacytoma
Head And Neck, 
Nantes, FR 

Philippe Moreau practices in Nantes, France. Mr. Moreau and is rated as an Elite expert by MediFind in the treatment of Plasmacytoma. His top areas of expertise are Multiple Myeloma, Plasmacytoma, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Bone Marrow Aspiration.

 
 
 
 
Learn about our expert tiers
Learn More
Youlia M. Kirova
Elite in Plasmacytoma
Elite in Plasmacytoma
Paris, FR 

Youlia Kirova practices in Paris, France. Kirova and is rated as an Elite expert by MediFind in the treatment of Plasmacytoma. Their top areas of expertise are Breast Cancer, Plasmacytoma, Mediastinal Tumor, Mastectomy, and Bone Marrow Aspiration.

What are the latest Plasmacytoma Clinical Trials?
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

Summary: The goal of this clinical research study is to learn about the safety of giving immune cells called natural killer (NK) cells with chemotherapy to patients with leukemia, lymphoma, or multiple myeloma. Immune system cells (such as NK cells) are made by the body to attack foreign or cancerous cells. Researchers think that NK cells you receive from a donor may react against cancer cells in your body...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Single-Arm, Open, Multi-Center Phase II Clinical Trial of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma Complicated by Extramedullary Plasmacytoma

Summary: All subjects will receive GR1803 injection until intolerable toxicity or investigator-assessed disease progression occurs (except in cases of disease progression due to discontinuation of the drug as a result of an adverse event) or until the subject has been administered the drug for 2 years or until the subject withdraws consent or until the investigator determines that the subject needs to be d...

Who are the sources who wrote this article ?

Published Date: May 10, 2022
Published By: Genetic and Rare Diseases Informnation Center